Jan Kaiserle

Jan Kaiserle

Medical Systems Advisor
Jan Kaiserle specializes in medical research and evidence-based medicine. He explores the latest advancements in medical science, clinical trials, and healthcare technologies to improve diagnosis, treatment, and disease prevention. His content bridges the gap between clinical research and practice, providing meaningful insights for healthcare professionals.
Red Queen Therapeutics Raises $55M to Tackle Diverse Viral Threats
Research & Development Red Queen Therapeutics Raises $55M to Tackle Diverse Viral Threats

The biotech landscape is abuzz with the launch of Red Queen Therapeutics, a startup that aims to revolutionize antiviral treatments. Backed by a $55 million investment from venture firm Apple Tree Partners and additional funding from the Biomedical Advanced Research and Development Authority

Biotech Updates: Workforce Cuts, FDA Approvals, and Clinical Outcomes
Research & Development Biotech Updates: Workforce Cuts, FDA Approvals, and Clinical Outcomes

The biotech industry has seen a flurry of activity, with companies undertaking significant workforce restructuring, achieving crucial FDA approvals, and navigating the complex landscape of clinical trials. These developments reflect both the challenges and advancements within the sector, offering a

FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor
Research & Development FDA Approves Leqselvi for Severe Alopecia Areata, A JAK Inhibitor

The FDA's recent approval of a new treatment for severe alopecia areata marks a significant advance in addressing this challenging condition. Deuruxolitinib, branded as Leqselvi and developed by Sun Pharmaceutical Industries, will now compete with existing treatments from Eli Lilly and Pfizer,

Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases
Research & Development Artiva’s $167M IPO Signals Shift to Allogeneic Therapies for Autoimmune Diseases

Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a broader

Is HilleVax's Norovirus Vaccine Viable for Adult Populations?
Research & Development Is HilleVax's Norovirus Vaccine Viable for Adult Populations?

HilleVax, a biotechnological firm previously in the spotlight for its experimental Norovirus vaccine, HIL-214, has made headlines again. After an extensive and ultimately disappointing Phase 2b trial in infants, the company is now strategizing a new target demographic: adults. Given the intricate

How Will Peptide Backbone Tweaks Revolutionize Drug Discovery?
Research & Development How Will Peptide Backbone Tweaks Revolutionize Drug Discovery?

Despite tremendous advancements in medical science, drug discovery remains a daunting challenge, particularly when it comes to illnesses involving complex protein interactions. Conventional drug development strategies fall short when faced with the vast network of protein-protein interactions

Asthma Treatments Expand with 90+ Pipelines by Global Firms
Research & Development Asthma Treatments Expand with 90+ Pipelines by Global Firms

As we witness a demanding push for the development of innovative asthma treatments, over 80 key companies globally have embarked on an ambitious journey. This initiative aims to create a robust arsenal of more than 90 therapeutic approaches, targeting a condition that continues to affect the

Tetra Pharm and Kvantify Partner to Innovate ECS Drug Discovery
Research & Development Tetra Pharm and Kvantify Partner to Innovate ECS Drug Discovery

The partnership between Tetra Pharm Technologies and Kvantify signifies a major step forward in the realm of drug discovery, particularly within the arena of the endocannabinoid system (ECS). This alliance is poised to not only speed up the discovery process but also holds the promise of yielding

S&P 500 Surge Signals Bright End; Biopharma Stocks Shine
Research & Development S&P 500 Surge Signals Bright End; Biopharma Stocks Shine

The financial markets have recently witnessed a significant uptick, particularly focusing on the robust performance of the S&P 500 index. With a history of early gains often translating into positive year-end outcomes, the current rise of over 10% within the first 100 trading days has set a hopeful

How Are Biopharma Layoffs Shaping Industry's Future?
Management & Regulatory How Are Biopharma Layoffs Shaping Industry's Future?

The biopharmaceutical industry is experiencing a profound transformation, marked by a wave of layoffs and strategic overhauls across companies of all sizes. Confronted with economic headwinds and the urgency to adapt, biopharma entities are taking decisive steps to shore up their operations. This

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later